Breast Cancer | Specialty

Has PARP Inhibition Finally Arrived in Breast Cancer?

March 12th 2017

The success of olaparib in a phase III trial and recent data for other emerging agents has reversed the PARP narrative in breast cancer, Kimberly Blackwell, MD, said in a presentation at the 34th Annual Miami Breast Cancer Conference.

Immunotherapy Combos on Horizon for Breast Cancer

March 12th 2017

Multiple ongoing clinical trials are evaluating various immunotherapy strategies for patients with breast cancer, with combinations representing the most potential for future success.

Dr. Brufsky on Choosing When to do a Multiparameter Genomic Assay

March 12th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses when to do a multiparameter genomic assay for a patient with early-stage breast cancer.

Dr. O'Shaughnessy on Differentiating Between CDK 4/6 Inhibitors

March 11th 2017

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses differentiating between CDK 4/6 inhibitors in breast cancer.

Study Shows Healthcare Utilization and Costs for mTNBC

March 11th 2017

Healthcare resource use and costs remain high among patients with metastatic triple-negative breast cancer, indicating a need for better targeted treatments for this patient class.

Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer Treatment

March 11th 2017

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses data supporting the elimination of anthracyclines in HER2-positive breast cancer treatment.

Novel Agents Improve Outcomes in HR+ Breast Cancer

March 11th 2017

Adding CDK4/6 and mTOR inhibitors to standard endocrine therapy has significantly improved outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer, William J, Gradishar, MD, explained in a presentation at the 34th Annual Miami Breast Cancer Conference.

Breast Surgeons Essential for Effective Genetic Testing

March 10th 2017

It is imperative that surgeons remain involved in genetic counseling to meet the immense unmet need that exists for patients with breast cancer, given a shortage of available genetic counselors.

Dr. Chagpar on Novel Agents for Neoadjuvant TNBC Treatment

March 10th 2017

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses novel agents for neoadjuvant triple-negative breast cancer (TNBC) treatment.

Ribociclib Effective in Elderly Patients With HR+/HER2- Breast Cancer

March 10th 2017

Adding ribociclib to frontline letrozole reduced the risk of disease progression or death by 40% in elderly patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to a subgroup analysis of the phase III MONALEESA-2 trial presented at the 34th Annual Miami Breast Cancer Conference.

Dr. Jahanzeb on the APHINITY and ExteNET Trials in Breast Cancer

March 10th 2017

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the APHINITY and ExteNET studies in breast cancer.

Eribulin/Pembrolizumab Combo Effective for TNBC

March 10th 2017

The combination of eribulin and pembrolizumab demonstrated promising objective response rates, including a complete response, for patients with metastatic triple-negative breast cancer.

Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer

March 10th 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.

Dr. Tanioka on the Results of CALGB 40601 in HER2+ Breast Cancer

March 8th 2017

Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

Dr. Kornblum on Results of PrECOG 0102 in Breast Cancer

March 6th 2017

Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the results from the PrECOG 0102 study, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

Adjuvant Pertuzumab Succeeds in Phase III HER2+ Breast Cancer Trial

March 2nd 2017

Adding pertuzumab (Perjeta) to trastuzumab (Herceptin) and chemotherapy reduced the risk of recurrence of invasive disease or death in patients with HER2-positive early breast cancer, according to findings from the phase III APHINITY study.

Breast Cancer Brain Metastases Require Personalized Approach

February 28th 2017

Carey Anders, MD, discusses available and emerging treatment options for patients with breast cancer that has metastasized to the brain.

Antibody-Drug Conjugates for TNBC

February 22nd 2017

Immunotherapy for TNBC

February 22nd 2017

BRCA1/2 Status and Homologous Repair Deficiency in TNBC

February 22nd 2017